Poster (1330P): Phase 2 Study of Pembrolizumab (Pemb) plus Plinabulin (Plin) and Docetaxel (Doc) for Patients (pts) with Metastatic NSCLC after Failure on First-line Immune Checkpoint Inhibitor Alone ...
Imugene Ltd (ASX:IMU, OTC:IUGNF, FRA:ILA) will present data from its lead cancer therapy candidate azer-cel in an oral ...
NMD Pharma will also present an update on the ongoing SYNAPSE-MG Phase 2b clinical trial of ignaseclant in generalized myasthenia gravis Aarhus, Denmark, 10 March 2026 – NMD Pharma A/S, a ...
DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing ...
The impact of new technologies in the care of patients with breast cancer is at the core of the IMPAKT conference on translational research in breast cancer. Abstract 12O - Molecular subtype of breast ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results